Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Schiller Website

John T. Schiller, Ph.D.

Selected Publications

1)  Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA, Porras C, Schiffman M, Rodriguez AC, Solomon D, Jimenez S, Schiller JT, Lowy DR, van Doorn LJ, Wacholder S, Kreimer AR.
Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica.
PLoS ONE. 8: e68329, 2013.
2)  Schiller JT, Lowy DR.
Virus Infection and Cancer: an Overview.
Recent Results in Cancer Research. 193: 1-10, 2013.
3)  Safaeian M, Kemp TJ, Pan DY, Porras C, Cecilia Rodriguez A, Schiffman M, Cortes B, Katki H, Wacholder S, Schiller JT, Gonzalez P, Penrose K, Lowy DR, Quint W, van Doorn LJ, Herrero R, Hildesheim A, Pinto LA.
Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: Results from the Costa Rica Vaccine Trial.
Hum Vaccin Immunother. 9, 2013.
4)  Day PM, Thompson CD, Schowalter RM, Lowy DR, Schiller JT.
Identification of a role for the trans-Golgi network in human papillomavirus 16 pseudovirus infection.
J. Virol. 87: 3862-70, 2013.
5)  Domingos-Pereira S, Decrausaz L, Derré L, Bobst M, Romero P, Schiller JT, Jichlinski P, Nardelli-Haefliger D.
Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital-tumor regression in mice.
Mucosal Immunol. 6: 393-404, 2013.
6)  Jagu S, Kwak K, Schiller JT, Lowy DR, Kleanthous H, Kalnin K, Wang C, Wang H, Chow LT, Huh WK, Jaganathan KS, Chivukula SV, Roden RB.
Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine.
J. Virol. [Epub ahead of print], 2013.
7)  Schiller JT, Castellsagué X, Garland SM.
A review of clinical trials of human papillomavirus prophylactic vaccines.
Vaccine. 30 Suppl 5: F123-38, 2012.
8)  Day PM, Pang YS, Kines RC, Thompson CD, Lowy DR, Schiller JT.
An HPV in vitro neutralization assay that recapitulates the in vivo process of infection provides a sensitive measure of L2 infection-inhibiting antibodies.
Clin Vaccine Immunol. 19: 1075-82, 2012.
9)  Schelhaas M, Shah B, Holzer M, Blattmann P, Kühling L, Day PM, Schiller JT, Helenius A.
Entry of human papillomavirus type 16 by actin-dependent, clathrin- and lipid raft-independent endocytosis.
PLoS Pathog. 8: e1002657, 2012.
10)  Çuburu N, Graham BS, Buck CB, Kines RC, Pang YY, Day PM, Lowy DR, Schiller JT.
Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses.
J. Clin. Invest. 122: 4606-20, 2012.
Click Here to View Expanded Bibliography.

This page was last updated on 9/9/2013.